financetom
Business
financetom
/
Business
/
Footwear maker Wolverine's Q3 profit beats estimates as price hikes boost margins
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Footwear maker Wolverine's Q3 profit beats estimates as price hikes boost margins
Nov 5, 2025 3:57 AM

Overview

* Wolverine Q3 revenue of $470.3 mln beats analyst expectations

* Adjusted EPS for Q3 at $0.36, exceeding analyst estimates

* Gross margin improved to 47.5% due to supply chain initiatives and price increases

Outlook

* Company expects 2025 revenue between $1.855 bln and $1.870 bln, up 6.0% to 6.8%

* Wolverine forecasts 2025 gross margin at 47.1%, up 280 basis points

* Company sees 2025 diluted EPS between $1.08 and $1.13

Result Drivers

* BRAND PERFORMANCE - Merrell, Saucony, and Sweaty Betty exceeded expectations, driving revenue growth

* GROSS MARGIN IMPROVEMENT - Supply chain cost initiatives, lower promotional activity, and price increases boosted gross margin

* SEGMENT DECLINES - Work Group and Wolverine brand saw revenue declines, with no detailed explanation provided

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $470.30 $462.96

Revenue mln mln (8

Analysts

)

Q3 Beat $0.36 $0.32 (8

Adjusted Analysts

EPS )

Q3 Gross 47.50%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the footwear peer group is "buy"

* Wall Street's median 12-month price target for Wolverine World Wide Inc ( WWW ) is $34.00, about 35.1% above its November 4 closing price of $22.08

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
J&J beats Wall Street estimates on strong drug sales
J&J beats Wall Street estimates on strong drug sales
Jul 17, 2024
(Reuters) -Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara. Shares of the drug and device maker rose 1.4% to $153.15 in choppy premarket trading. Revenue of $22.4 billion surpassed the consensus estimate of $22.3 billion, according to LSEG data. Adjusted...
BlackBerry Up 0.8% In US Premarket As Introduces CylanceMDR Pro, a Managed Detection and Response Service Powered by AI
BlackBerry Up 0.8% In US Premarket As Introduces CylanceMDR Pro, a Managed Detection and Response Service Powered by AI
Jul 17, 2024
06:23 AM EDT, 07/17/2024 (MT Newswires) -- BlackBerry Limited ( BB ) on Wednesday launched CylanceMDR Pro, a managed detection and response (MDR) service built on an Open XDR platform powered by AI. According to Wednesday's statement, the solution is designed to tackle the growing challenges of modern cybersecurity and is for businesses looking to :advance their cybersecurity capabilities without...
Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug
Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug
Jul 17, 2024
06:20 AM EDT, 07/17/2024 (MT Newswires) -- Adverum Biotechnologies ( ADVM ) said Wednesday that a 26-week interim analysis of its mid-stage trial of its novel gene therapy candidate, Ixo-vec, in patients with wet age-related macular degeneration showed the drug has a potential best-in-class product profile. Among two sets of 29 patients each receiving different dosages of Ixo-vec, patients needed...
VF to Sell Supreme Brand to EssilorLuxottica for $1.5 Billion in Cash
VF to Sell Supreme Brand to EssilorLuxottica for $1.5 Billion in Cash
Jul 17, 2024
06:22 AM EDT, 07/17/2024 (MT Newswires) -- VF (VFC) said Wednesday that it entered into a definitive agreement to sell its Supreme brand to EssilorLuxottica for $1.5 billion in cash. The Supreme apparel and accessories brand runs a digital-first business and 17 stores in the US, Asia and Europe, the company said. The transaction is expected to close by the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved